CGuard Prime Carotid Stent System
InspireMD, Ltd. · Decision date Mar 16, 2026
What did the FDA decide?
FDA records P240029/S002 as a supplement to PMA P240029, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Mar 16, 2026.
FDA approval order statement
the introduction of an additional stent crimper
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Mar 16, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P240029/S002
- Regulatory pathway
- PMA supplement
- Applicant
- InspireMD, Ltd.
- Product code
- NIM
- Decision code
- OK30
- Decision date
- Mar 16, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stent, carotid.
- Applicant
- InspireMD, Ltd.
- Product code
- NIM
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P240029/S002 received
Application receipt date recorded by FDA.
P240029/S001 · Related supplement
CGuard Prime Carotid Stent System
P240029/S002 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P240029. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P240029
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
CGuard Prime Carotid Stent SystemP240029/S001 | InspireMD, Ltd. | PMA supplement | Feb 20, 2026 | FDA |
Explore the linked device profile
Other records with product code NIM
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
PROTEGE GPS AND PROTEGE RX CAROTID STENT SYSTEMSP060001/S060 | Medtronic Vascular, Inc. | PMA supplement | Nov 5, 2026 | FDA |
| Contego Medical, Inc. | PMA supplement | Nov 4, 2026 | FDA | |
| Medtronic Vascular, Inc. | PMA supplement | Oct 16, 2026 | FDA | |
| Contego Medical, Inc. | PMA supplement | Jul 29, 2026 | FDA | |
| Medtronic Vascular, Inc. | PMA supplement | Jul 10, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
InspireMD, Ltd.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 6303 Waterford District Dr., Suite 215, Miami, FL, 33126
Sources and methodology
- Original FDA record: P240029/S002
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



